HK$37.86
7.57%
Hong Kong, Oct 10, 10:08 am CET
ISIN
KYG970081173
Symbol
2269
Index

WuXi Biologics Stock price

HK$37.86
+0.26 0.69% 1M
+18.64 96.98% 6M
+20.30 115.60% YTD
+19.84 110.10% 1Y
-9.14 19.45% 3Y
-33.61 47.02% 5Y
+28.44 302.05% 10Y
+28.44 302.05% 20Y
Hong Kong, Closing price Fri, Oct 10 2025
-3.10 7.57%

Key metrics

Basic
Market capitalization
HK$167.4b
Enterprise Value
HK$159.3b
Net debt
positive
Cash
HK$13.7b
Shares outstanding
4.1b
Valuation (TTM | estimate)
P/E
35.1 | 30.6
P/S
7.6 | 7.0
EV/Sales
7.3 | 6.7
EV/FCF
82.9
P/B
3.4
Financial Health
Equity Ratio
73.4%
Return on Equity
8.0%
ROCE
10.7%
ROIC
11.0%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
HK$21.9b | HK$23.9b
EBITDA
- | HK$8.7b
EBIT
HK$6.1b | HK$6.8b
Net Income
HK$4.6b | HK$5.0b
Free Cash Flow
HK$1.9b
Growth (TTM | estimate)
Revenue
17.2% | 17.2%
EBITDA
- | 27.1%
EBIT
44.5% | 28.3%
Net Income
59.4% | 37.4%
Free Cash Flow
661.3%
Margin (TTM | estimate)
Gross
42.7%
EBITDA
- | 36.4%
EBIT
27.8%
Net
20.9% | 21.1%
Free Cash Flow
8.8%
More
EPS
HK$1.1
FCF per Share
HK$0.5
Short interest
-
Employees
13k
Rev per Employee
HK$1.6m
Show more

Is WuXi Biologics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,999 stocks worldwide.

WuXi Biologics Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a WuXi Biologics forecast:

27x Buy
82%
6x Hold
18%

Analyst Opinions

33 Analysts have issued a WuXi Biologics forecast:

Buy
82%
Hold
18%

Financial data from WuXi Biologics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
21,907 21,907
17% 17%
100%
- Direct Costs 12,563 12,563
10% 10%
57%
9,344 9,344
29% 29%
43%
- Selling and Administrative Expenses 2,510 2,510
3% 3%
11%
- Research and Development Expense 837 837
3% 3%
4%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 6,085 6,085
45% 45%
28%
Net Profit 4,584 4,584
59% 59%
21%

In millions HKD.

Don't miss a Thing! We will send you all news about WuXi Biologics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. Its services include testing; clinical drug substance cGMP manufacture; commercial drug substance cGMP manufacture; drug product cGMP fill and finish; antibody drug conjugates; regulatory affairs; and technologies and platforms. The company was founded on May 24, 2010 and is headquartered in Wuxi, China.

Head office Cayman Islands
CEO Zhi Chen
Employees 12,575
Founded 2010
Website www.wuxibiologics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today